dupilumab

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND Dupilumab is a fully human anti-interleukin-4 receptor α monoclonal antibody that blocks both interleukin-4 and… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Review
2017
Review
2017
Dupilumab (Dupixent®) is a fully human monoclonal antibody directed against the interleukin (IL)-4 receptor α (IL-4Rα) subunit… (More)
Is this relevant?
Highly Cited
2017
Highly Cited
2017
 
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody, inhibits interleukin-4 and interleukin-13… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
IMPORTANCE Dupilumab has demonstrated efficacy in patients with asthma and atopic dermatitis, which are both type 2 helper T-cell… (More)
  • table 2
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND Data from early-stage studies suggested that interleukin (IL)-4 and IL-13 are requisite drivers of atopic dermatitis… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Severe atopic dermatitis (AD) has a high unmet need for effective and safe therapeutics. In early-phase trials… (More)
Is this relevant?
Highly Cited
2014
Review
2014
Review
2014
Simultaneously with the steady progress towards a better knowledge of the pathobiology of asthma, the potential usefulness of… (More)
  • figure 1
  • figure 2
Is this relevant?